Detalhe da pesquisa
1.
Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Biol Blood Marrow Transplant
; 22(2): 277-283, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26343949